Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial

Background: Rates of adverse events with sorafenib were higher in the DECISION trial in radioactive iodine-refractory, advanced differentiated thyroid cancer (DTC) than in trials of sorafenib for other tumor types. One possible explanation is that sarcopenia, a known predictive factor of toxicity in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Thyroid
Main Authors: Huillard, Olivier, Jouinot, Anne, Tlemsani, Camille, Brose, Marcia S., Arrondeau, Jennifer, Meinhardt, Gerold, Fellous, Marc, De Sanctis, Yoriko, Schlumberger, Martin, Goldwasser, Francois
Formato: Artigo
Idioma:Inglês
Publicado em: Mary Ann Liebert, Inc., publishers 2019
Assuntos:
Thyroid Cancer and Nodules
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6918875/
https://ncbi.nlm.nih.gov/pubmed/31860408
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/thy.2018.0784
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados